Thoratec seeks go-ahead for Canadian trials:
This article was originally published in Clinica
Thoratec Laboratories has submitted an application to the Canadian government to begin clinical trials of its prosthetic coronary artery bypass graft (CABG). The Aria CABG, which incorporates the company's proprietary biomaterial Thoralon, will initially be targeted at the 20% of all bypass patients who have few or no suitable native vessels. The 330-patient trial is expected to last one to two years following the completion of patient enrolment, said the Pleasanton, California-based company. It plans to seek approval to begin a US trial of the device later this year.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.